Crescent Biopharma, Inc.
The purpose of this study is to determine the safety and tolerability of monotherapy CR-001 and identify the maximum tolerated dose (MTD), and/or optimal biologic dose and Recommended Phase 2 Dose(s) (RP2D) in participants with locally advanced or metastatic solid tumors.
The study will be 4 parts: dose escalation, backfill, dose expansion and dose optimization cohorts. The study will follow a stepwise approach, beginning with a typical dose escalation in participants with selected indications of advanced solid tumors. Additional participants will enroll in the backfill part at select dose levels that have been previously cleared for safety by the safety review committee. Dose expansion will enroll 7 cohorts of participants who will receive CR-001 in combination with chemotherapy. In dose optimization, participants will be randomized to one of two CR-001 dose l…
Key Inclusion Criteria * Life expectancy ≥ 3 months * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 - 1 * Adequate organ function and hematologic reserve based on laboratory parameters * Have measurable disease defined by RECIST v1.1 * For Backfill, Dose Expansion and Dose Optimization: Willingness to provide recent archival tumor tissue sample or willingness to undergo biopsy * Tumor Indication specific inclusion criteria: * For dose escalation or backfill: progressing from, intolerant to, or ineligible for (due to unavailability or contraindication) local standard…
Intravenous Infusion
Intravenous Infusion
Oral
Intravenous Infusion
Intravenous Infusion
Intravenous Infusion
Intravenous Infusion
Intravenous Infusion
Oral
Intravenous Infusion + Oral